Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High - Here's Why

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $3.89 and last traded at $3.88, with a volume of 2500599 shares changing hands. The stock had previously closed at $3.59.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Jefferies Financial Group reiterated a "buy" rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Piper Sandler lowered Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target on the stock. in a research note on Monday, November 11th. Finally, HC Wainwright lifted their price target on Xeris Biopharma from $6.00 to $6.60 and gave the company a "buy" rating in a research note on Monday, November 11th.

Xeris Biopharma Trading Down 5.5 %

The firm has a market cap of $559.05 million, a P/E ratio of -8.33 and a beta of 2.61. The business has a 50-day moving average of $3.48 and a two-hundred day moving average of $3.14.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Xeris Biopharma by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock worth $26,778,000 after acquiring an additional 133,738 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Xeris Biopharma by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock valued at $11,364,000 after purchasing an additional 17,956 shares during the period. AIGH Capital Management LLC lifted its stake in shares of Xeris Biopharma by 17.8% in the 4th quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company's stock valued at $8,729,000 after purchasing an additional 389,192 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Xeris Biopharma by 31.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock valued at $7,115,000 after purchasing an additional 500,120 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after purchasing an additional 502,853 shares during the period. Institutional investors own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.